Plasma proteomic profiling reveals KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis.
Panpan ZhangMengdi LiYuqi ZhangChaofeng LianJinlei SunYujie HeWenlu HuLimei WangTianfang LiShengyun LiuYusheng ZhangPublished in: Clinical rheumatology (2023)
Immune response-related proteins are significantly altered in patients with anti-MDA5+ DM patients. KRT19 could be a potential biomarker for anti-MDA5+ DM patients. Key Points • What is already known on this topic? Anti-MDA5+ DM is a distinctive subtype of IIM. Plasma immune response-related proteins panel needs to be investigated. • What this study adds? Plasma protein profiling of immune response-related proteins significantly altered in patients with idiopathic inflammatory myopathies (IIM), especially in anti-MDA5+ DM patients. • How this study might affect research, practice, or policy? KRT19 could be a potential biomarker in patients with anti-MDA5+ dermatomyositis.
Keyphrases
- immune response
- end stage renal disease
- ejection fraction
- breast cancer cells
- chronic kidney disease
- newly diagnosed
- healthcare
- prognostic factors
- primary care
- metabolic syndrome
- dendritic cells
- type diabetes
- oxidative stress
- high resolution
- mental health
- idiopathic pulmonary fibrosis
- interstitial lung disease
- inflammatory response
- drug induced